NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved Qiagen's Therascreen KRAS RGQ PCR companion test to pick out best responders to Amgen's colorectal cancer drug Vectibix (panitumumab).

Simultaneously, the agency also approved late last week Vectibix in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, for first-line treatment of patients with wild-type KRAS metastatic colorectal cancer. The latest approval converts the accelerated approval for Vectibix into full approval.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.